Paul A. Monach, MD, PhD
Associate Professor
Boston University School of Medicine
Dept of Medicine
Rheumatology (Arthritis)

MD, University of Chicago
PhD, University of Chicago



My research is focused on clinical and translational research in vasculitis: biomarkers, genetics, and clinical trials.

I have led studies aimed at identifying new markers that could improve diagnosis, staging, assessment of current disease activity, and predicting the future course of disease, using proteins detectable in the blood or urine and gene expression profiles in blood cells.

I have also led candidate genes studies in vasculitis and has been involved in the planning and recruitment for genome-wide association studies in multiple forms of vasculitis.

I have participated in most multi-center clinical trials conducted over the past 10 years in the US, in various vasculitides.

This work has been conducted through NIH-funded consortia: the Vasculitis Clinical Research Consortium and the RAVE/ITN Study Group. In addition, I have been a member of the Immunological Genome Project Consortium and contributed data on gene expression in mouse neutrophils to that effort.


Abatacept (CTLA4_Ig) For the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyaugiitis (Wegener's) (ABROGATE)
03/10/2015 - 03/09/2020 (PI)
Cleveland Clinic Foundation Bristol-Myers Squibb


A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculiti
02/28/2017 - 02/27/2020 (PI)
ChemoCentryx, Inc.


Vasculitis Clinical Research Foundation
09/01/2017 - 08/31/2018 (PI)
Trustees of the University of Pennsylvania NIH NIAMS
5U54AR057319-15

Vasculitis Clinical Research Consortium-ARAMIS Pilot
01/01/2017 - 08/31/2018 (Co-PI)
PI: Christina Lam, MD
Trustees of the University of Pennsylvania NIH NIAMS
5U54AR057319-14

Adaptation and Validation of PROMIS for use in Vasculitis
09/15/2012 - 08/31/2018 (PI)
Trustees of the University of Pennsylvania NIH NIAMS
5R01AR064153-04

Identification of Shared Molecular Targets
07/01/2017 - 06/30/2018 (PI)
Trustees of the University of Pennsylvania NIH NCATS
9U01TR001263-11

Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921
12/24/2015 - 06/30/2018 (PI)
GlaxoSmithKline, Inc.


Novel Methods for the Conduct of Clinical Trials
06/01/2016 - 05/31/2018 (PI)
Trustees of the University of Pennsylvania NIH NHLBI
4R01HL115041-04

Prospective, Observational Safety Study of Patients with Wegener's Granulomatosis (Granulomatosis with Polyangitis) or Microscopic Polyangitis Treated with Rituximab
03/01/2012 - 02/28/2018 (PI)
Hoffmann-La Roche Inc (Foreign)


Prospective, Observational Safety Study of Patients with Wegener's Granulomatosis (Granulomatosis with Polyangitis) or Microscopic Polyangitis Treated with Rituximab
03/01/2012 - 02/28/2018 (PI)
Hoffmann-La Roche Inc (Foreign)


Showing 10 of 23 results. Show All Results


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Cornec D, Kabat BF, Mills JR, Cheu M, Hummel AM, Schroeder DR, Cascino MD, Brunetta P, Murray DL, Snyder MR, Fervenza F, Hoffman GS, Kallenberg CGM, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, St Clair EW, Stone JH, Barnidge DR, Specks U. Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology (Oxford). 2018 Apr 01; 57(4):639-650. PMID: 29340623.
     
  2. Springer JM, Monach P, Cuthbertson D, Carette S, Khalidi NA, McAlear CA, Pagnoux C, Seo P, Warrington KJ, Ytterberg SR, Hoffman G, Langford C, Hamilton T, Foell D, Vogl T, Holzinger D, Merkel PA, Roth J, Hajj-Ali RA. Serum S100 Proteins as a Marker of Disease Activity in Large Vessel Vasculitis. J Clin Rheumatol. 2018 Feb 22. PMID: 29470262.
     
  3. Kermani TA, Sreih AG, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, Koening CL, Langford CA, McAlear CA, Monach PA, Moreland L, Pagnoux C, Seo P, Warrington KJ, Ytterberg SR, Merkel PA. Evaluation of damage in giant cell arteritis. Rheumatology (Oxford). 2018 Feb 01; 57(2):322-328. PMID: 29112740.
     
  4. Rhee RL, Davis JC, Ding L, Fervenza FC, Hoffman GS, Kallenberg CGM, Langford CA, McCune WJ, Monach PA, Seo P, Spiera R, St Clair EW, Specks U, Stone JH, Merkel PA. The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. Clin J Am Soc Nephrol. 2018 Feb 07; 13(2):251-257. PMID: 29371340.
     
  5. Geetha D, Sethi S, De Vriese AS, Specks U, Kallenberg CGM, Lim N, Spiera R, St Clair EW, Merkel PA, Seo P, Monach PA, Lepori N, Fessler BJ, Langford CA, Hoffman GS, Sharma R, Stone JH, Fervenza FC. Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. Am J Nephrol. 2017; 46(3):231-238. PMID: 28881339.
     
  6. Wallace ZS, Miloslavsky EM, Cascino M, Unizony SH, Lu N, Hoffman GS, Kallenberg CGM, Langford CA, Merkel PA, Monach PA, Seo P, Spiera R, St Clair EW, Specks U, Brunetta P, Choi HK, Stone JH. Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken). 2017 Jul; 69(7):1004-1010. PMID: 27696762; DOI: 10.1002/acr.23099;.
     
  7. Merkel PA, Xie G, Monach PA, Ji X, Ciavatta DJ, Byun J, Pinder BD, Zhao A, Zhang J, Tadesse Y, Qian D, Weirauch M, Nair R, Tsoi A, Pagnoux C, Carette S, Chung S, Cuthbertson D, Davis JC, Dellaripa PF, Forbess L, Gewurz-Singer O, Hoffman GS, Khalidi N, Koening C, Langford CA, Mahr AD, McAlear C, Moreland L, Seo EP, Specks U, Spiera RF, Sreih A, St Clair EW, Stone JH, Ytterberg SR, Elder JT, Qu J, Ochi T, Hirano N, Edberg JC, Falk RJ, Amos CI, Siminovitch KA. Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Arthritis Rheumatol. 2017 May; 69(5):1054-1066. PMID: 28029757; DOI: 10.1002/art.40034;.
     
  8. Cunin P, Penke LR, Thon JN, Monach PA, Jones T, Chang MH, Chen MM, Melki I, Lacroix S, Iwakura Y, Ware J, Gurish MF, Italiano JE, Boilard E, Nigrovic PA. Megakaryocytes compensate for Kit insufficiency in murine arthritis. J Clin Invest. 2017 May 01; 127(5):1714-1724. PMID: 28375155; DOI: 10.1172/JCI84598;.
     
  9. Monach PA. Assessing Performance of Internal Medicine Residents. JAMA. 2017 03 28; 317(12):1276-1277. PMID: 28350919; DOI: 10.1001/jama.2017.0890;.
     
  10. Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, Seo P, Moreland LW, Weisman M, Koening CL, Sreih AG, Spiera R, McAlear CA, Warrington KJ, Pagnoux C, McKinnon K, Forbess LJ, Hoffman GS, Borchin R, Krischer JP, Merkel PA. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. Arthritis Rheumatol. 2017 Apr; 69(4):846-853. PMID: 28133931; DOI: 10.1002/art.40037;.
     
Showing 10 of 91 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 91 publications over 22 distinct years, with a maximum of 14 publications in 2015 and 2017

YearPublications
19901
19911
19931
19951
19961
19991
20011
20031
20041
20052
20074
20081
20093
20105
20114
20127
201313
20146
201514
20165
201714
20184
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Biomarkers
Vasculitis

Available to Mentor as: (Review Mentor Role Definitions):
  • Research / Scholarly Mentor
Contact for Mentoring:


75 E. Newton St Evans Building
Boston MA 02118
Google Map


Monach's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department